Abcam, ab119566, Human VEGFA ELISA Kit

Size: 1 x 96Tests
Human VEGFA ELISA Kit is a sandwich ELISA designed to quantify Human VEGFA with a sensitivity of 7.9 pg/mL. - Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader - Wide dynamic range - quantifies 15.6 - 1000 pg/mL - Cited in over 20 publications
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 7.9 pg/mL,
Range:15.6 - 1000 pg/mL,
Assay Platform:Microplate

Product details:
Human VEGFA ELISA Kit ab119566 is a sandwich ELISA to measure Human VEGFA in serum, plasma, cell culture supernatant with a sensitivity of 7.9 pg/ml.
How the assay works
VEGFA specific antibodies have been precoated onto 96-well plates. Standards and test samples are added to the wells and then incubated at room temperature. After washing, a Biotin-conjugated anti-Human VEGFA detection antibody is added then incubated at room temperature. Following washing Streptavidin-HRP conjugate is added to each well, incubated at room temperature then again washed. TMB is added and then catalyzed by HRP to produce a blue color product that changes into yellow after addition of an acidic stop solution. The density of yellow coloration is directly proportional to the amount of VEGFA captured on the plate.
Produced using a non-baculovirus
Escherichia coli
expression system.
Assay Specificity
Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details
Human VEGFA ELISA Kit ab119566 protocol summary
1. Add standard or sample to appropriate wells. Incubate the plate
2. Wash and add Biotinylated mouse anti-TGF beta 1 monoclonal antibody to appropriate wells. Incubate the plate.
3. Wash and add prepared Streptavidin-HRP Conjugate to appropriate wells. Incubate at room temperature
4. Wash and add TMB Substrate to each well
5. Add Stop Solution to each well. Read immediately

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.
Biological function summary
VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.
Pathways
Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.
VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.